Full Text Journal Articles by
Author Radoslav Chekerov

Advertisement

Find full text journal articles






Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group.

Fabian Trillsch, Sven Mahner, Bastian Czogalla, Miriam Rottmann, Radoslav Chekerov, Elena Ioana Braicu, Gülten Oskay-Öczelik, Pauline Wimberger, Rolf Richter, Jalid Sehouli,

<h4>Objective</h4>Patients with platinum-resistant ovarian cancer (PROC) have a high need for reliable prognostic markers. Since significance of primary platinum resistance (PPR) versus secondary platinum resistance (SPR) was identified for patients receiving anti-angiogenic therapy, it has not been confirmed for chemotherapy only.<h4>Methods</h4>PROC patients from 3 prospective trials of the NOGGO study ... Read more >>

J Gynecol Oncol (Journal of gynecologic oncology)
[2021, 32(3):e37]

Cited: 0 times

View full text PDF listing >>



Angiosarcomas of Primary Gynecologic Origin - A Case Series and Review of the Literature.

Lukas Chinczewski, Eliane Tabea Taube, Felix Wilhelm Feldhaus, Lisa Antonia DrÖge, Radoslav Chekerov, Mustafa Zelal Muallem, Klaus Pietzner, Jalid Sehouli, Sara Alavi,

<h4>Background/aim</h4>Angiosarcoma of primary gynecologic origin is an extremely rare and highly malignant tumor of endothelial origin with a 5-year survival rate of less than 35%. To date, only 61 cases have been described in the literature. The aim of this study was to present more cases and discuss potential therapy ... Read more >>

Anticancer Res (Anticancer research)
[2020, 40(10):5743-5750]

Cited: 1 time

View full text PDF listing >>



Advertisement

Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).

Irena Rohr, Sara Alavi, Rolf Richter, Maren Keller, Radoslav Chekerov, Gülten Oskay-Özcelik, Michaela Heinrich, Cagatay Taskiran, Florence Joly, Regina Berger, Andreas du Bois, Andreja Gornjec, Ignace Vergote, Patriciu Achimas-Cadariu, Domenica Lorusso, Johanna Maenpaa, Jalid Sehouli,

<h4>Background</h4>Maintenance therapy induces remission and prolongs disease free interval in primary and recurrent ovarian disease. For the treatment decision making process, aspects of quality of life and patients' preferences are crucial, despite the fact that scientific data are lacking. Therefore, we conducted this European-wide study in patients with ovarian cancer.<h4>Methods</h4>A ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2020, 30(4):509-514]

Cited: 1 time

View full text PDF listing >>



Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer.

Hagen Kulbe, Raik Otto, Silvia Darb-Esfahani, Hedwig Lammert, Salem Abobaker, Gabriele Welsch, Radoslav Chekerov, Reinhold Schäfer, Duska Dragun, Michael Hummel, Ulf Leser, Jalid Sehouli, Elena Ioana Braicu,

Detection of epithelial ovarian cancer (EOC) poses a critical medical challenge. However, novel biomarkers for diagnosis remain to be discovered. Therefore, innovative approaches are of the utmost importance for patient outcome. Here, we present a concept for blood-based biomarker discovery, investigating both epithelial and specifically stromal compartments, which have been ... Read more >>

Cells (Cells)
[2019, 8(7):]

Cited: 6 times

View full text PDF listing >>



Preservation of stemness in high-grade serous ovarian cancer organoids requires low Wnt environment

Karen Hoffmann, Hilmar Berger, Hagen Kulbe, Sukanija Thillainadarasan, Hans-Joachim Mollenkopf, Tomasz Zemojtel, Eliane Taube, Silvia Darb-Esfahani, Mandy Mangler, Jalid Sehouli, Radoslav Chekerov, Elena Braicu, Thomas Meyer, Mirjana Kessler,

<h4>Summary</h4> High-grade serous ovarian cancer (HGSOC) likely originates from the fallopian tube (FT) epithelium. Here, we established 15 organoid lines from HGSOC primary tumor deposits that closely match the parental tumor mutational profile and phenotype. We found that Wnt pathway activation leads to growth arrest of these cancer organoids. Moreover, ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients.

Jacek Przemyslaw Grabowski, Rolf Richter, Hannah Rittmeister, Radoslav Chekerov, Hannah Woopen, Jalid Sehouli,

<h4>Background/aim</h4>Chemotherapy-associated toxicity is one of the limiting factors regarding treatment efficacy, patient outcome and quality of life in this collective. Underweight or obese patients represent a major group in which the therapy seems to be more challenging. The aim of this analysis was to evaluate the impact of BMI on ... Read more >>

Anticancer Res (Anticancer research)
[2018, 38(10):5853-5858]

Cited: 1 time

View full text PDF listing >>



Participation of elderly gynecological cancer patients in clinical trials.

Katharina Prieske, Fabian Trillsch, Gülten Oskay-Özcelik, Radoslav Chekerov, Christiane Bleich, Leticia Oliveira-Ferrer, Donata Grimm, Sascha Kuerti, Volkmar Mueller, Anna Suling, Barbara Schmalfeldt, Jalid Sehouli, Sven Mahner, Linn Woelber,

<h4>Background</h4>Elderly patients are underrepresented in clinical trials in gynecological cancer, even though they are disproportionally often affected. This study aimed to evaluate the disposition and apprehension of elderly patients toward study participation.<h4>Methods</h4>112 elderly gynecological cancer patients (median age 70) were surveyed in a multicenter cross-sectional study. Besides fitness, state of ... Read more >>

Arch Gynecol Obstet (Archives of gynecology and obstetrics)
[2018, 298(4):797-804]

Cited: 3 times

View full text PDF listing >>



Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Radoslav Chekerov, Felix Hilpert, Sven Mahner, Ahmed El-Balat, Philipp Harter, Nikolaus De Gregorio, Claudius Fridrich, Susanne Markmann, Jochem Potenberg, Ralf Lorenz, Guelten Oskay-Oezcelik, Marcus Schmidt, Petra Krabisch, Hans-Joachim Lueck, Rolf Richter, Elena Ioana Braicu, Andreas du Bois, Jalid Sehouli, , ,

<h4>Background</h4>Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer.<h4>Methods</h4>We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2018, 19(9):1247-1258]

Cited: 18 times

View full text PDF listing >>



Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.

Tingting Sun, Ilary Ruscito, Desislava Dimitrova, Radoslav Chekerov, Hagen Kulbe, Udo Baron, Véronique Blanchard, Pierluigi Benedetti Panici, Silvia Darb-Esfahani, Jalid Sehouli, Sven Olek, Elena Ioana Braicu,

<h4>Objectives</h4>The aim of the present study was to assess in a large cohort of primary epithelial ovarian cancer patients the incidence and the clinical effect of BRCA1 genetic and epigenetic silencing mechanisms.<h4>Methods</h4>A total of 188 primary epithelial ovarian cancer patients, treated between 2000 and 2011 at the Charité University Hospital ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2017, 27(8):1658-1665]

Cited: 3 times

View full text PDF listing >>



Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.

Radoslav Chekerov, Philipp Harter, Stefan Fuxius, Lars Christian Hanker, Linn Woelber, Lothar Müller, Peter Klare, Wolfgang Abenhardt, Yoana Nedkova, Isil Yalcinkaya, Georg Heinrich, Harald Sommer, Sven Mahner, Pauline Wimberger, Dominique Koensgen-Mustea, Rolf Richter, Gülten Oskay-Oezcelik, Jalid Sehouli, ,

<h4>Background</h4>Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients (≥65 years) for p.o. ... Read more >>

Gynecol Oncol Res Pract (Gynecologic oncology research and practice)
[2017, 4:6]

Cited: 3 times

View full text PDF listing >>



A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).

Jalid Sehouli, Oliver Tomè, Desislava Dimitrova, Oumar Camara, Ingo Bernhard Runnebaum, Hans Werner Tessen, Beate Rautenberg, Radoslav Chekerov, Mustafa Zelal Muallem, Michael Patrick Lux, Tanja Trarbach, Gerald Gitsch,

<h4>Objective</h4>In recurrent ovarian cancer (ROC), there is a high demand on effective therapies with a mild toxicity profile. Treosulfan is an alkylating agent approved as oral (p.o.) and intravenous (i.v.) formulation for the treatment of recurrent ovarian cancer. Data on safety and efficacy for either formulation are rare. For the ... Read more >>

J Cancer Res Clin Oncol (Journal of cancer research and clinical oncology)
[2017, 143(3):541-550]

Cited: 4 times

View full text PDF listing >>



Influence of Chemotherapy on the Antioxidant Status of Human Skin.

Bich Na Lee, Sora Jung, Maxim E Darvin, Jan Eucker, Dagmar Kühnhardt, Jalid Sehouli, Radoslav Chekerov, Alexa Patzelt, Harald Fuss, Ruo-Xi Yu, Jürgen Lademann,

<h4>Background</h4>Palmoplantar erythrodysesthesia is a frequent dermal side-effect during chemotherapy. Previous investigations showed radical formation subsequent to doxorubicin infusion and preventative and therapeutic effects of an antioxidant-containing ointment.<h4>Patients and methods</h4>Using a non-invasive vivomeasuring system (Biozoom®; Biozoom Services GmbH, Kassel, Germany) changes in the antioxidant status (as measured by relative carotenoid concentration) ... Read more >>

Anticancer Res (Anticancer research)
[2016, 36(8):4089-4093]

Cited: 1 time

View full text PDF listing >>



Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).

Irena Rohr, Elena I Braicu, Abdelaziz En-Nia, Michaela Heinrich, Rolf Richter, Radoslav Chekerov, Ralf Dechend, Harald Heidecke, Duska Dragun, Reinhold Schäfer, Xenia Gorny, Jonathan A Lindquist, Sabine Brandt, Jalid Sehouli, Peter R Mertens,

<h4>Introduction</h4>The cold shock Y-box binding protein-1 (YB-1) fulfills important roles in regulating cell proliferation and differentiation. Overexpression occurs in various tumor cells. Given the existence of extracellular YB-1 we set out to determine the diagnostic, predictive and prognostic role of serum YB-1/p18 for patients with primary epithelial ovarian cancer (EOC).<h4>Methods</h4>The ... Read more >>

Cytokine (Cytokine)
[2016, 85:157-164]

Cited: 7 times

View full text PDF listing >>



Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium.

Irena Rohr, Robert Zeillinger, Michaela Heinrich, Nicole Concin, Ignace Vergote, Mani Nassir, Sven Mahner, Els VAN Nieuwenhuysen, Fabian Trillsch, Dan Cacsire-Tong, Radoslav Chekerov, Jalid Sehouli, Elena I Braicu,

<h4>Background/aim</h4>IGF-I (insulin growth factor 1) is crucially involved in cellular proliferation. Moreover, deregulation of IGF-I has been shown to be relevant in the carcinogenesis of various tumor entities. However, the impact of IGF-I in epithelial ovarian cancer (EOC) is unclear. In the present study, we investigated the predictive and prognostic ... Read more >>

Anticancer Res (Anticancer research)
[2016, 36(3):1015-1022]

Cited: 2 times

View full text PDF listing >>



Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.

Khayal Gasimli, Elena Ioana Braicu, Mani Nassir, Rolf Richter, Aygun Babayeva, Radoslav Chekerov, Silvia Darb-Esfahani, Jalid Sehouli, Mustafa Zelal Muallem,

<h4>Objective</h4>The main goal of the current study was to compare survival differences among subgroups of primary ovarian cancer patients in International Federation of Gynecology and Obstetrics (FIGO) stages IIIC and IIIA1 after complete tumor debulking surgery.<h4>Methods</h4>A total of 218 patients with primary ovarian cancer who received complete cytoreductive surgery were ... Read more >>

Ann Surg Oncol (Annals of surgical oncology)
[2016, 23(4):1279-1286]

Cited: 2 times

View full text PDF listing >>



The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.

Christian Marth, Andreas du Bois, Christian Schauer, Andreas du Bois, Antonio Casado, Ignace Vergote, José Maria del Campo, Athina Goudopoulou, Eric Pujade-Lauraine, Ilan Bruchim, Nicoletta Colombo, Sandro Pignata, Jonathan Ledermann, Radoslav Chekerov, Mansoor Raza Mirza, Anneke Westermann, Ros Glasspool, Cagatay Taskiran, Mathias Fehr, David Cibula,

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2015, 25(6):1094-1095]

Cited: 0 times

View full text PDF listing >>



Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.

Radoslav Chekerov, Gabriele Kaltenecker, Dietmar Reichert, Thomas Göhler, Peter Klare, Gülten Oskay-Özcelik, Uwe Sauer, Arthur Wischnik, Ursula Vehling-Kaiser, Martin Becker, Ulrich Hutzschenreuter, Andreas Ammon, Elke Heidrich-Lorsbach, Jalid Sehouli,

<h4>Background</h4>Data on routine systemic treatment of patients with ovarian cancer are currently available only to a limited degree. The alkylating agent treosulfan is approved in oral (p.o.) and intravenous (i.v.) form for the treatment of ovarian carcinoma. The present non-interventional study analyzed the clinical use of treosulfan in Germany, evaluating ... Read more >>

Anticancer Res (Anticancer research)
[2015, 35(12):6869-6875]

Cited: 4 times

View full text PDF listing >>



Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.

Khayal Gasimli, Elena Ioana Braicu, Rolf Richter, Radoslav Chekerov, Jalid Sehouli,

<h4>Purpose</h4>The peritoneal cancer index (PCI) is used to refer gastrointestinal malignancy patients to either palliative or curative management of their peritoneal carcinomatosis. The aim of this retrospective study was to evaluate the prognostic value of the PCI in patients with primary advanced epithelial ovarian cancer (EOC) after complete cytoreductive surgery.<h4>Methods</h4>PCI ... Read more >>

Ann Surg Oncol (Annals of surgical oncology)
[2015, 22(8):2729-2737]

Cited: 9 times

View full text PDF listing >>



Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Klaus Pietzner, Ignace Vergote, Armando Santoro, Radoslav Chekerov, Frederik Marmé, Per Rosenberg, Holger Martinius, Hilke Friccius-Quecke, Jalid Sehouli,

Malignant ascites is a common phenomenon in cancer patients. It poses a great challenge to the clinician, because of limited treatment options and strong impairment of the quality of life of the often palliative patients. The SECIMAS study investigated the feasibility of a re-challenge with four catumaxomab intraperitoneal infusions in ... Read more >>

Med Oncol (Medical oncology (Northwood, London, England))
[2014, 31(12):308]

Cited: 4 times

View full text PDF listing >>



Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium.

Elena Ioana Braicu, Toon Van Gorp, Mani Nassir, Rolf Richter, Radoslav Chekerov, Khayal Gasimli, Dirk Timmerman, Ignace Vergote, Jalid Sehouli,

<h4>Background</h4>Borderline tumors of the ovary (BOT) are a distinct entity of ovarian tumors, characterized by lack of stromal invasion. Recent studies postulated that the presence of invasive implants, incomplete staging, fertility sparing surgery and residual tumor after surgery are major prognostic factors for BOT. There are no biomarkers that can ... Read more >>

J Ovarian Res (Journal of ovarian research)
[2014, 7:49]

Cited: 10 times

View full text PDF listing >>



Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.

Elena Ioana Braicu, Khayal Gasimli, Rolf Richter, Mani Nassir, Sherko Kümmel, Jens-Uwe Blohmer, Isil Yalcinkaya, Radoslav Chekerov, Iulia Ignat, Andra Ionescu, Monika Mentze, Christina Fotopoulou, Carmen Pop, Werner Lichtenegger, Jalid Sehouli, , ,

AIM: The aim of the current study was to analyze the type of variations in expression profiles of matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9), tissue inhibitor of metalloproteinase 2 (TIMP2), and vascular endothelial growth factor A (VEGFA) before and after radiochemotherapy in patients with locally advanced FIGO stage ... Read more >>

Anticancer Res (Anticancer research)
[2014, 34(1):385-391]

Cited: 17 times

View full text PDF listing >>



Survey among German gynecologists on the clinical management of patients with sarcomas of the uterus.

Frank Chih-Kang Chen, Matthias David, Rolf Richter, Mustafa Zelal Muallem, Radoslav Chekerov, Jalid Sehouli,

<h4>Aim</h4>To gain more information about the knowledge of the clinical management of uterine sarcoma.<h4>Materials and methods</h4>This survey was performed among members of the North-Eastern German Society of Gynecological Oncology (NOGGO) and the German Society of Psychosomatic Medicine in Gynecology and Obstetrics (DGPFG) on the treatment of uterine sarcomas.<h4>Results</h4>Altogether, 374 gynecologists ... Read more >>

Anticancer Res (Anticancer research)
[2013, 33(8):3375-3381]

Cited: 2 times

View full text PDF listing >>



HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.

Elena Ioana Braicu, Radoslav Chekerov, Rolf Richter, Carmen Pop, Mani Nassir, Hanna Loefgren, Florin Stamatian, Mustafa Zelal Muallem, Christina Hall, Christina Fotopoulou, Jalid Sehouli, Klaus Pietzner,

<h4>Background</h4>Epithelial ovarian cancer (EOC) remains the main cause of mortality due to gynecological malignancies. Optimal tumor debulking and platinum response are the most important prognostic factors for overall survival (OS) in primary EOC. In the setting of recurrence, the role of cytoreduction is not clear. A critical point is to ... Read more >>

Ann Surg Oncol (Annals of surgical oncology)
[2014, 21(3):955-962]

Cited: 14 times

View full text PDF listing >>



Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.

Ignace B Vergote, Radoslav Chekerov, Frederic Amant, Philipp Harter, Antonio Casado, Janusz Emerich, Thomas Bauknecht, Kambiz Mansouri, Scott P Myrand, Tuan S Nguyen, Peipei Shi, Jalid Sehouli,

<h4>Purpose</h4>Enzastaurin is an oral serine/threonine kinase inhibitor antitumor agent. Our phase II trial tested the efficacy and safety of enzastaurin added to a standard carboplatin/paclitaxel chemotherapy regimen in patients with newly diagnosed advanced ovarian cancer.<h4>Patients and methods</h4>This was a randomized, placebo-controlled study in patients with International Federation of Gynecology and ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2013, 31(25):3127-3132]

Cited: 11 times

View full text PDF listing >>



Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy.

Juergen Lademann, Anja Martschick, Franziska Kluschke, Heike Richter, Joachim W Fluhr, Alexa Patzelt, Sora Jung, Radoslav Chekerov, Maxim E Darvin, Norbert Haas, Wolfram Sterry, Leonhard Zastrow, Jalid Sehouli,

<h4>Background</h4>Pegylated liposomal doxorubicin (PLD) is a highly efficient chemotherapeutic; however, it induces dermal side effects such as palmar-plantar erythrodysesthesia (PPE) in up to 80% of cases, probably by being emitted with the sweat onto the skin surface.<h4>Aim</h4>The aim of the present study was to examine whether a topically applied ointment ... Read more >>

Skin Pharmacol Physiol (Skin pharmacology and physiology)
[2014, 27(2):66-70]

Cited: 7 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1061 s